Evan J Carder

Medicinal chemistry | Organic chemistry | Chemical biology | I'm interested in cancer and drug discovery - science that creates molecules with therapeutic value

[Evan J Carder @EvanJCarder]

Natural products (NP) are a great inspiration for novel therapeutics. Liu et. al. nicely demonstrated in @angew_chem the inclusion of NP features to develop complex NP-derived fragments as a strategy to discover new bioactive chemical matter. Check it out! https://t.co/8ObY134Ic2

[Evan J Carder @EvanJCarder]

"I always thought you coped with failure or you didn't cope with failure. I never thought anyone loved failure...Not only weren't they discouraged by failure, they didn't even think they were failing. They thought they were learning." Carol Dweck #Mindset

[Evan J Carder @EvanJCarder]

Nice commentary by @DrLCSquare in @NatureChemistry discussing and encouraging collaborative academic-industrial research. Improved open communication and further sponsorship can continue to strengthen this symbiotic relationship. Check it out! https://t.co/b7z2U3ixz8

[Evan J Carder @EvanJCarder]

Targeted cancer therapies are commonly challenged by mutations that result in drug resistance. @DanaFarber scientists showed an elegant strategy by developing mutant-selective allosteric EGFR degraders and employing targeted polypharmacology. Check it out! https://t.co/v4hcSpXCwF

[Evan J Carder @EvanJCarder]

Nice work in @ACSCentSci by the @CraigMCrews team toward the development of the first reported #PROTAC to induce endogenous KRAS(G12C) degradation. Continued achievement toward challenging the notion of "undruggable." Check it out! https://t.co/JUHjfqxl0N

[Evan J Carder @EvanJCarder]

An interesting @JMedChem perspective discussing the life cycle of SARS-CoV-2 and potential therapeutic strategies. For current and future novel coronaviruses "it is of utmost importance to design drugs acting as pancoronavirus antivirals..." Check it out! https://t.co/7AeSCNQ9xS

[Evan J Carder @EvanJCarder]

Outsourcing scientific responsibilities to contract research organizations (CROs) is an integral strategy to drug discovery/development. A recent perspective in @JMedChem describes what to consider when choosing a CRO. Check it out! https://t.co/V4CaQ9VOPn

[Evan J Carder @EvanJCarder]

Nice webinar by @CDDVault discussing "PROTACs - Developing New Therapies through Targeted Protein Degradation." Panelists include Stewart Fisher (@C4Therapeutics), Eric Fischer and Nathanael Gray (@DanaFarber). Check it out! https://t.co/SfbVkRU9L8

[Evan J Carder @EvanJCarder]

PROTACs are impressive tools used to explore biology and potentially treat disease. This elegant primer in @CellCellPress by @GMBurslem and @CraigMCrews provides a workflow for PROTAC development and discusses the benefits of this technology. Check it out! https://t.co/fxzvD62QfU

[Evan J Carder @EvanJCarder]

The phosphorylation status of a protein can directly influence its function. As an initial study, @genentech demonstrated the use of targeted heterobifunctional molecules that direct phosphatase mediated protein dephosphorylation. Very cool! Check it out! https://t.co/F8ZNJQ5nBr

[Evan J Carder @EvanJCarder]

Asking a small-molecule to inhibit the PCSK9/LDL receptor complex proved challenging. Alternatively, @Merck scientists identified/developed an allosteric binder used to fashion a bifunctional ligand that elicited PCSK9 protein degradation. Check it out! https://t.co/K6W8PTZ7XF

[Evan J Carder @EvanJCarder]

Great presentation from @georg_e_winter on his work toward the development of thalidomide-based protacs for targeted protein degradation - a very exciting time for the field! Check it out! https://t.co/ODcZB1TJDT

[Evan J Carder @EvanJCarder]

An enjoyable drug discovery presentation by Dr. Michael Jung @uclachem on the development of prostate cancer drug enzalutamide. Great strategy to influence a transcription factor driven disease - disrupting AR translocation into the nucleus. Check it out! https://t.co/uo1JTsPabE

[Evan J Carder @EvanJCarder]

Should we place greater focus on developing multi-targeted agents? Nice perspective in @JMedChem on strategies to rationally design multi-targeted directed ligands. Can artificial intelligence soon assist with this multi-dimensional pursuit? Check it out! https://t.co/bE76bjna5y

[Evan J Carder @EvanJCarder]

For those interested in topics related to drug discovery, Drug Discovery World (@DDWJournal) developed a nice podcast that elegantly provides audio versions of their published articles. Convenient way to learn while on the move! Check it out! https://t.co/2hRic5evKL

[Evan J Carder @EvanJCarder]

Interesting commentary by @GSK scientists on employing high-throughput experimentation (HTE) for multivariate screening instead of one factor at a time reaction optimization. Perhaps we should embrace a HTE mindset. Check it out! https://t.co/YnmPvYiRXe

[Evan J Carder @EvanJCarder]

Excellent research presentation on iron catalyzed carbonyl-olefin metathesis and oxygen atom transfer by @SchindlerLab! Easy to recognize why @cenmag selected her as a Talented 12. Check it out! https://t.co/pgbpBVnqCp

[Evan J Carder @EvanJCarder]

Fragment based drug discovery is a powerful approach - a target-based method that often relies on structural information of ligand/protein complex. A nice perspective in @CellChemBiol discusses advancing fragments without a crystal structure. Check it out! https://t.co/m5KTcXvgaz

[Evan J Carder @EvanJCarder]

"The clearer you are about what you want in life, the luckier you will find yourself becoming" from Sandler Success Principles by @Dave_Mattson @BruceSeidman Check it out!

[Evan J Carder @EvanJCarder]

Great round table discussion on a career in chemistry featuring Chancellor Yundong Wu and Professor Ken Houk. "Family is very important to career development"